Korro Bio price target lowered to $90 from $155 at Oppenheimer

Oppenheimer lowered the firm’s price target on Korro Bio (KRRO) to $90 from $155 and keeps an Outperform rating on the shares following quarterly results. The firm notes KRRO-110/AATD Phase 1/2a REWRITE SAD interim readout remains on track in the second half of 2025. While Oppenheimer’s fundamental outlook on Korro remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data; accordingly, the firm increases the discount rate from 30% to 40%.